dc.description.abstract | Introduction. Cerebral toxoplasmosis is a primary opportunistic infection in HIV/AIDS
patients. Cerebral toxoplasmosis is closely associated with poor treatment outcomes in HIV
patients due to an inadequate immune system. However, it does not rule out the possibility of
treatment outcomes resulting in disability due to lesions in the brain parenchymal or patients
recovering from T. gondii infection without disability. Objective. To identify factors related to
treatment outcomes in HIV/AIDS patients with cerebral toxoplasmosis at RSUP Haji Adam
Malik Medan from 2022 to 2023. Method. This study used a predictive multivariate analytical
method with a cross-sectional design. The inclusion criteria for this research were HIV/AIDS
patients with cerebral toxoplasmosis documented in the medical records of RSUP Haji Adam
Malik Medan from 2022 to 2023. Result and Discussion. In bivariate analysis, ten variables
were tested using chi-square test or fisher’s exact test, and only the leukocyte count showed a
significant p-value (p = 0,029). Logistic regression test results indicated a p-value for the
leukocyte count of 0,050 (OR 0,096; CI 0,009-1,004), lymphocyte count of 0,770 (OR 0,792;
CI 0,116-3,777), and eosinophil count of 0,124 (OR 0,238; CI 0,038-1,484). Conclusion. No
variable significantly influences patient treatment outcomes. | en_US |